Piramal Pharma Limited (IN:PPLPHARMA)
:PPLPHARMA
Want to see IN:PPLPHARMA full AI Analyst Report?
Top Page
Piramal Pharma Limited
(PPLPHARMA)
Select Model
Select Model
Rating:55Neutral
Price Target:
₹170.00
▼(-11.76% Downside)
Action:ReiteratedDate:03/20/26
The score is primarily supported by decent financial fundamentals (revenue growth, strong gross margins, and manageable leverage), but is held back by very weak technicals (price below all key moving averages with negative MACD) and mixed valuation signals due to a negative P/E and minimal dividend yield.
Positive Factors
High gross margins
A gross margin near 64.7% reflects durable product and service mix advantages (specialty generics and CDMO work) that can absorb input cost swings and fund R&D or capacity expansion. High gross margins support long-term reinvestment and pricing flexibility if the mix is maintained.
Negative Factors
Volatile free cash flow
Significant FCF volatility undermines the company’s ability to consistently fund capex, service debt, or return capital. Even with stable operating cash flow metrics at times, erratic FCF hampers strategic investments and raises dependence on external financing for sustained growth over multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
A gross margin near 64.7% reflects durable product and service mix advantages (specialty generics and CDMO work) that can absorb input cost swings and fund R&D or capacity expansion. High gross margins support long-term reinvestment and pricing flexibility if the mix is maintained.
Read all positive factors
Piramal Pharma Limited (PPLPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹219.92B
Dividend Yield0.08%
Average Volume (3M)264.14K
Price to Earnings (P/E)―
Beta (1Y)0.69
Revenue Growth-0.87%
EPS Growth-522.01%
CountryIN
Employees6,719
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.70
Shares Outstanding1,329,248,200
10 Day Avg. Volume501,791
30 Day Avg. Volume264,138
Financial Highlights & Ratios
PEG Ratio0.84
Price to Book (P/B)3.72
Price to Sales (P/S)3.34
P/FCF Ratio132.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.2
Revenue Forecast (FY)₹102.13B
Piramal Pharma Limited Business Overview & Revenue Model
Company Description
Piramal Pharma Limited operates as a pharmaceutical company. It sells a portfolio of pharma products, as well as provides various pharma services, including injection, HPAPI, etc. The company was incorporated in 2020 and is based in Mumbai, India....
How the Company Makes Money
Piramal Pharma Limited primarily makes money through three business lines: (1) Contract Development and Manufacturing (CDMO): it earns service revenue by providing end-to-end capabilities to innovator pharmaceutical companies, including process an...
Piramal Pharma Limited Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
70
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 88.46B | 90.61B | 81.06B | 70.32B | 64.72B | 29.00B |
| Gross Profit | 45.33B | 54.89B | 48.48B | 40.32B | 37.91B | 16.46B |
| EBITDA | 14.11B | 16.49B | 13.67B | 8.94B | 12.60B | 8.94B |
| Net Income | -237.40M | 911.30M | 178.20M | -1.86B | 3.76B | 5.71B |
Balance Sheet | ||||||
| Total Assets | 161.89B | 156.78B | 153.12B | 145.23B | 127.97B | 57.57B |
| Cash, Cash Equivalents and Short-Term Investments | 7.44B | 5.21B | 5.02B | 6.60B | 3.79B | 1.62B |
| Total Debt | 48.51B | 48.56B | 47.10B | 56.37B | 41.28B | 1.74B |
| Total Liabilities | 81.16B | 75.52B | 74.00B | 77.49B | 61.00B | 16.56B |
| Stockholders Equity | 80.74B | 81.25B | 79.11B | 67.73B | 66.97B | 41.01B |
Cash Flow | ||||||
| Free Cash Flow | 4.57B | 2.28B | 2.92B | -4.81B | -1.23B | -233.90M |
| Operating Cash Flow | 8.90B | 8.92B | 10.05B | 4.84B | 7.66B | 347.20M |
| Investing Cash Flow | -4.68B | -4.77B | -4.34B | -13.39B | -18.12B | -43.83B |
| Financing Cash Flow | -3.61B | -4.41B | -4.22B | 8.18B | 7.94B | 44.94B |
Piramal Pharma Limited Technical Analysis
Negative
192.65
Price Trends
151.41
Negative
162.17
Negative
180.28
Negative
Market Momentum
-0.71
Negative
54.37
Neutral
83.69
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PPLPHARMA, the sentiment is Negative. The current price of 192.65 is above the 20-day moving average (MA) of 141.90, above the 50-day MA of 151.41, and above the 200-day MA of 180.28, indicating a neutral trend. The MACD of -0.71 indicates Negative momentum. The RSI at 54.37 is Neutral, neither overbought nor oversold. The STOCH value of 83.69 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:PPLPHARMA.
Piramal Pharma Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹395.24B | 27.58 | ― | 0.28% | 8.92% | 24.73% | |
70 Outperform | ₹212.54B | 173.10 | ― | 0.35% | 34.49% | 107.17% | |
69 Neutral | ₹216.59B | 40.22 | ― | 0.69% | 11.01% | 38.67% | |
66 Neutral | ₹321.75B | 36.01 | ― | 0.86% | 9.47% | 17.05% | |
61 Neutral | ₹282.43B | 27.13 | ― | 1.07% | 6.70% | 20.25% | |
55 Neutral | ₹219.92B | -41.77 | ― | 0.08% | -0.87% | -522.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:PPLPHARMA
Piramal Pharma Limited
168.75
-46.06
-21.44%
IN:ASTRAZEN
AstraZeneca Pharma India Limited
8,576.10
-233.36
-2.65%
IN:GLAND
Gland Pharma Ltd.
1,773.30
373.39
26.67%
IN:IPCALAB
IPCA Laboratories Limited
1,537.45
126.46
8.96%
IN:JBCHEPHARM
JB Chemicals & Pharmaceuticals Ltd.
2,047.85
464.14
29.31%
IN:PFIZER
PFIZER LIMITED
4,791.70
639.24
15.39%
Piramal Pharma Limited Corporate Events
Piramal Critical Care and Blue-Zone Partner to Recycle Waste Anaesthetic Gases
Feb 5, 2026
Piramal Critical Care, Inc. and Canada-based Blue-Zone Technologies Ltd. have entered into a collaboration to deploy full lifecycle technology for capturing, collecting and recycling waste anaesthetic gases, marrying Blue-Zone’s proprietary ...
Piramal Pharma to Acquire Kenalog Injectable Portfolio from Bristol-Myers Squibb
Jan 28, 2026
Piramal Pharma’s step-down wholly owned subsidiary, Piramal Critical Care B.V., has signed definitive agreements to acquire Kenalog and associated injectable corticosteroid brands from Bristol-Myers Squibb for an upfront US$35 million, plus ...
Piramal Pharma Strengthens Senior Management, Appoints Interim Company Secretary
Jan 28, 2026
Piramal Pharma Limited has expanded its senior management ranks by designating four executives as Senior Management Personnel, covering key functions such as quality, mergers and acquisitions, legal, and human resources, reflecting a push to stren...
Piramal Pharma Posts Higher Profit Despite Softer Revenue in Q3 FY26
Jan 28, 2026
Piramal Pharma Limited’s board has approved the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025. For the December quarter, standalone revenue from operations stood at ₹1,19...
Piramal Pharma Posts Muted Q3 FY26 Results but Signals Early Recovery and Continued Expansion
Jan 28, 2026
Piramal Pharma Limited reported a 3% year-on-year decline in consolidated revenue from operations to ₹2,140 crore for Q3 FY26 and a 4% drop to ₹6,117 crore for the nine months ended December 31, 2025, with EBITDA down 32% in the quarte...
Piramal Pharma Reshuffles Senior Management and Appoints Interim Company Secretary
Jan 28, 2026
Piramal Pharma Limited’s board has expanded its senior management team by designating four officials as Senior Management Personnel, including the Chief Quality Officer, President – Mergers and Acquisitions, General Counsel and Chief H...
Piramal Pharma Posts Q3 Loss as CDMO Weakness Weighs, Signals Early Demand Recovery
Jan 28, 2026
Piramal Pharma reported a weak performance for the third quarter and first nine months of FY26, with consolidated revenue from operations declining 3% year-on-year in Q3 to ₹2,140 crore and 4% in the nine-month period to ₹6,117 crore, ...
Piramal Pharma Revamps Senior Management, Appoints New Compliance Chief
Jan 28, 2026
Piramal Pharma Limited has overhauled its senior management structure, designating four executives as Senior Management Personnel: Chief Quality Officer Rashida Najmi, President – Mergers and Acquisitions Jatin Lal, General Counsel Sandeep R...
Piramal Pharma Revamps Senior Management and Key Compliance Role
Jan 28, 2026
Piramal Pharma Limited has announced a series of senior leadership changes, expanding its cadre of Senior Management Personnel with the additional designation of Chief Quality Officer Rashida Najmi, President – Mergers and Acquisitions Jatin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.